Sydnexis
- Company typePrivate
- Founded2014
- HeadquartersDel Mar, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
Sydnexis firmographics
Firmographics- Name
- Sydnexis
- Legal name
- Sydnexis, Inc.
- Website
- https://sydnexis.com
- Company type
- Private
- Founded year
- 2014
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
Sydnexis industry classification
Industry- Product category
- Pediatric Ophthalmic Pharmaceuticals
- NAICS
- Scientific Research and Development Services (5417)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro industry
- Rare Ophthalmology Disorder TherapiesRare Pediatric & Congenital Disorder Therapies
Keywords
Where Sydnexis is headquartered
LocationHeadquarters
- HQ city
- Del Mar
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Sydnexis business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Others
Revenue model
- Licensing Royalties (Santen Partnership): Sydnexis licenses SYD-101 to Santen S.A. for commercialization in Europe, the Middle East, and Africa under the brand name Ryjunea®. The company receives royalty payments from Santen's sales in these territories. Approvals have been obtained in the EU and UK, with initial launch in Germany.
- Pharmaceutical Product Sales (US Market): Upon FDA approval, Sydnexis intends to commercialize SYD-101 directly in the US market as the first and only FDA-approved pharmaceutical treatment for pediatric progressive myopia for children ages 3-14.
Go-to-market motion2 records
Distribution channels2 records
Marketing channels5 records
Sydnexis product offering
Product offeringCore offering
Sydnexis develops SYD-101, a proprietary low-dose atropine 0.01% eye drop formulation designed to slow the progression of pediatric progressive myopia in children aged 3-14. The compound features near-neutral pH, enhanced ocular tissue permeability, BAK preservation, and 3-year room temperature stability. SYD-101 is approved in the EU and UK (marketed as Ryjunea®) through licensing partner Santen S.A., and is under FDA review for the US market.
Product overview
Sydnexis is a biopharmaceutical company developing a single lead product candidate, SYD-101, which is a proprietary low-dose atropine 0.01% eye drop for treating pediatric progressive myopia. The product is administered once nightly and is being studied for use in children as young as 3 years old. SYD-101 features novel formulation attributes including near-neutral pH for tolerability, enhanced ocular tissue permeability, and room-temperature stability. The product is currently approved in the European Union and UK under the brand name Ryjunea® through licensing partner Santen S.A., and is under regulatory review for FDA approval in the United States where it would represent the first FDA-approved pharmaceutical treatment for pediatric progressive myopia.
Differentiator
Problem solved
Functional benefit
Products and services
- SYD-101 SYD-101 is Sydnexis's proprietary investigational low-dose atropine 0.01% eye drop formulation intended to slow the progression of pediatric progressive myopia in children aged 3-14. The formulation features near-neutral pH for ocular tolerability, enhanced ocular tissue permeability demonstrated in preclinical models, BAK preservation for sustained bioavailability, and stability for up to 3 years at room temperature. It is administered once nightly and was studied in the Phase 3 STAR trial, the largest global clinical program in pediatric myopia enrolling 852 children across 47 sites in the US and Europe.
Quantifiable outcome
- 47.9% reduction in myopia progression at 12 months in children aged 3-12
- +3 more outcomes
Companies that use Sydnexis
Customer profileSegments3 records
Ideal customer profiles1 record
Sydnexis technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Sydnexis partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Santen S.A.coreSydnexis licensed SYD-101 to Santen S.A. for commercialization in Europe, the Middle East, and Africa. Santen commercializes the product under the brand name Ryjunea® (low-dose atropine 0.1 mg/ml). This partnership followed the 2021 Series B financing and represents the company's primary international commercialization strategy.
Scale indicators5 records
Recent moves6 records
Expansion highlights5 records
Sydnexis competitors and assessment
Company assessmentDirect peers
- Vyluma: Late-stage clinical biopharma developing NVK002, a low-dose atropine formulation for pediatric myopia progression. Directly competes with SYD-101 in the same indication, patient population, and regulatory pathway.
- Eyenovia: Ophthalmic pharma developing pediatric myopia therapies (including MicroPine) using its proprietary Optejet delivery platform. Directly competes in the PPM pharmaceutical space with a differentiated delivery technology.
Emerging players
- Arctic Vision: Asia-focused ophthalmic biotech developing ARVN302, a low-dose atropine for myopia. Operates in the same therapeutic category and uses a similar regulatory strategy, but primary focus is on the Greater China market.
- Ocular Therapeutix: Ophthalmic biopharma developing sustained-release therapies for anterior segment diseases. Comparable as a small-cap, late-clinical ophthalmic biotech pursuing regulatory and commercial milestones in eye care.
- Harrow Health: US-focused ophthalmic specialty pharma commercializing branded anterior segment and surface disease therapies. Comparable as a small-cap ophthalmic pharma pursuing niche regulatory and commercial opportunities.
Broad incumbents
- CooperVision (MiSight): Large contact lens manufacturer whose MiSight 1 day is the first FDA-approved product for myopia progression control. Competes with SYD-101 in the same PPM indication via a non-pharmaceutical specialty contact lens modality.
- Bausch + Lomb: Major ophthalmic pharma and device company with broad pediatric vision care offerings. Represents a potential strategic acquirer and competitor across multiple PPM management modalities including lenses and emerging pharmacotherapies.
- Santen Pharmaceutical: Japanese ophthalmic specialty pharma and Sydnexis's EU/Middle East/Africa licensing partner for Ryjunea®. A leading global ophthalmic player with deep myopia presence, particularly across Asia and Europe.
- Alcon: Global leader in eye care with broad surgical and vision care franchises. Competes with Sydnexis in pediatric vision care via specialty lenses and is a potential strategic acquirer for emerging ophthalmic pharma assets.
- AbbVie (Allergan Aesthetics / Eye Care): Global biopharma with a significant ophthalmology franchise inherited from Allergan. Operates in adjacent retinal and anterior segment categories and is a potential strategic acquirer of PPM assets.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Sydnexis social profiles
Digital presenceSydnexis financial estimates
Financial estimateRevenue estimate
Valuation estimate
Sydnexis leadership team
Management profileNumber of profiles
Profiles16 records
Sydnexis funding detail
Funding detailFunding overview
Funding rounds2 records
Investors6 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Sydnexis M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Sydnexis
What does Sydnexis do?
Sydnexis develops SYD-101, a proprietary low-dose atropine 0.01% eye drop formulation designed to slow the progression of pediatric progressive myopia in children aged 3-14. The compound features near-neutral pH, enhanced ocular tissue permeability, BAK preservation, and 3-year room temperature stability. SYD-101 is approved in the EU and UK (marketed as Ryjunea®) through licensing partner Santen S.A., and is under FDA review for the US market.
Is Sydnexis a public or private company?
Sydnexis is a private company. It is classified as venture growth investor backed and is currently operating.
When was Sydnexis founded?
Sydnexis was founded in 2014. It employs 11 to 50 people.
Where is Sydnexis based?
Sydnexis is headquartered in Del Mar, United States, in the North America region.
How does Sydnexis make money?
Two revenue lines are on record. Licensing Royalties (Santen Partnership) is the primary driver. The others are pharmaceutical Product Sales (US Market).
Who are Sydnexis's main competitors?
Direct peers on record are Vyluma and Eyenovia. Emerging players are Arctic Vision, Ocular Therapeutix and Harrow Health. Broad incumbents are CooperVision (MiSight), Bausch + Lomb, Santen Pharmaceutical, Alcon and AbbVie (Allergan Aesthetics / Eye Care).
Does Sydnexis have an API?
No public API is recorded for Sydnexis.
What industry is Sydnexis in?
Sydnexis's product category is Pediatric Ophthalmic Pharmaceuticals. Its primary akta.pro industry code is HLAIAIAK, Rare Ophthalmology Disorder Therapies, with a secondary code of HLAIAIAN, Rare Pediatric & Congenital Disorder Therapies. Its NAICS code is 5417 and its SIC code is 2834.